Study: Omicron evades some but not all monoclonal antibodies

Several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the omicron variant now sweeping across the United States, researchers reported Jan. 19 in the journal Nature Medicine.

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

The anti–SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination

Immune Escape Mechanisms of SARS-CoV-2 Delta and Omicron Variants against Two Monoclonal Antibodies That Received Emergency Use Authorization

SARS-CoV-2 vaccine-induced antibodies protect against Omicron breakthrough infection - ScienceDirect

SARS-CoV-2 Study Forecasts Emergence of Immune Escape Variants

Monoclonal antibodies lock down SARS-CoV-2 spike: Trends in Immunology

How monoclonal antibodies work against omicron variant - ABC News

How Omicron escapes from antibodies, MIT News

Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies - eBioMedicine

The ability of therapeutic monoclonal antibodies to neutralize SARS-CoV-2 Omicron BA.2 variant

Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

Interaction Analysis of the Spike Protein of Delta and Omicron Variants of SARS-CoV-2 with hACE2 and Eight Monoclonal Antibodies Using the Fragment Molecular Orbital Method

Why the Omicron BA.5 Variant Evades Vaccines